SCHEMBL16015165

SCHEMBL16015165

O=C(NC(c1ccccc1)[C@@H](O)c1ccccc1)[C@@H]1CCCN1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.55
CYP2D6 P10635 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C19 P33261 1/20 0.55
CTSC P53634 4/20 0.53
CYP2C9 P11712 1/20 0.51
TSHR P16473 1/20 0.51
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
LMNA P02545 1/20 0.41
AOC3 Q16853 1/20 0.41
SLC6A3 Q01959 4/20 0.40
SLC6A2 P23975 2/20 0.40
SLC6A4 P31645 2/20 0.40
DHFR P00374 1/20 0.40
GPR88 Q9GZN0 1/20 0.40
MAN2A1 Q16706 1/20 0.40
MAN1B1 Q9UKM7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12333752 1.00 CYP3A4 (0.55) CYP3A4CYP2D6CYP1A2CYP2C19CTSC
SCHEMBL16015166 1.00 CYP3A4 (0.55) CYP3A4CYP2D6CYP1A2CYP2C19CTSC
SCHEMBL16376134 1.00 CYP3A4 (0.55) CYP3A4CYP2D6CYP1A2CYP2C19CTSC
SCHEMBL16139975 1.00 CYP3A4 (0.55) CYP3A4CYP2D6CYP1A2CYP2C19CTSC
SCHEMBL20193704 0.93 CYP3A4 (0.52) CYP3A4CYP2D6CYP1A2CYP2C19CTSC
SCHEMBL13974186 0.85 CYP3A4 (0.57) CYP3A4CYP2D6CYP1A2CYP2C19CTSC
SCHEMBL24056571 0.83 LMNA (0.60) CYP3A4CYP2D6CYP1A2CYP2C19CTSC
SCHEMBL7305357 0.83 LMNA (0.60) CYP3A4CYP2D6CYP1A2CYP2C19CTSC
SCHEMBL24057819 0.83 LMNA (0.60) CYP3A4CYP2D6CYP1A2CYP2C19CTSC
SCHEMBL7313727 0.81 RECQL (0.62) CYP3A4CYP2D6CYP1A2CYP2C19CTSC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829208-B2 Process for the preparation of darunavir and darunavir intermediates MAPI PHARMA LTD. (IL) 2014-09-09 US disclosed